{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:38:37Z","timestamp":1785411517672,"version":"3.56.0"},"reference-count":10,"publisher":"American Association for Cancer Research (AACR)","issue":"4","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Summary:<\/jats:title>\n                  <jats:p>Carlson and colleagues demonstrate that SETBP1 mutations promote leukemic self-renewal by recruiting MYST acetyltransferase complexes (KAT7\/KAT6A) to chromatin, where H3K14ac and H3K23ac marks are deposited on promoter sites for key stemness genes. Genetic deletion or pharmacologic inhibition of KAT7\/KAT6A was shown to shut down this SETBP1-associated self-renewal program and promote myeloid differentiation of SETBP1-mutant cells.<\/jats:p>\n                  <jats:p>See related article by Carlson et al., p. 606<\/jats:p>","DOI":"10.1158\/2643-3230.bcd-26-0136","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:16:41Z","timestamp":1780316201000},"page":"506-508","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["KATs in the MYST: A New Therapeutic Vulnerability for\n                    <i>SETBP1<\/i>\n                    -Mutated Myeloid Malignancies"],"prefix":"10.1158","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9996-9003","authenticated-orcid":false,"given":"Mark","family":"Soto","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05cf8a891","id-type":"ROR","asserted-by":"publisher"}],"name":"Albert Einstein College of Medicine 1 Department of Cell Biology, , Bronx, New York."},{"id":[{"id":"https:\/\/ror.org\/05cf8a891","id-type":"ROR","asserted-by":"publisher"}],"name":"Albert Einstein College of Medicine 2 Department of Medical Oncology, , Bronx, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1367-1167","authenticated-orcid":false,"given":"Kira","family":"Gritsman","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05cf8a891","id-type":"ROR","asserted-by":"publisher"}],"name":"Albert Einstein College of Medicine 1 Department of Cell Biology, , Bronx, New York."},{"id":[{"id":"https:\/\/ror.org\/05cf8a891","id-type":"ROR","asserted-by":"publisher"}],"name":"Albert Einstein College of Medicine 2 Department of Medical Oncology, , Bronx, New York."},{"name":"3Department of Medical Oncology, Montefiore Medical Center, Bronx, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"2026070103103090600_bib1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nm1393","article-title":"Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1","volume":"12","author":"Ott","year":"2006","journal-title":"Nat Med"},{"key":"2026070103103090600_bib2","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ng.2696","article-title":"Somatic SETBP1 mutations in myeloid malignancies","volume":"45","author":"Makishima","year":"2013","journal-title":"Nat Genet"},{"key":"2026070103103090600_bib3","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1038\/s41375-022-01646-6","article-title":"Correction: mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia","volume":"36","author":"Carratt","year":"2022","journal-title":"Leukemia"},{"key":"2026070103103090600_bib4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia","volume":"45","author":"Piazza","year":"2013","journal-title":"Nat Genet"},{"key":"2026070103103090600_bib5","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1182\/blood-2011-10-388710","article-title":"SETBP1 promotes the self-renewal of murine myeloid progenitors via activation of Hoxa9 and Hoxa10","volume":"119","author":"Oakley","year":"2012","journal-title":"Blood"},{"key":"2026070103103090600_bib6","doi-asserted-by":"crossref","first-page":"103679","DOI":"10.1016\/j.isci.2021.103679","article-title":"Recruitment of MLL1 complex is essential for SETBP1 to induce myeloid transformation","volume":"25","author":"Nguyen","year":"2021","journal-title":"iScience"},{"key":"2026070103103090600_bib7","first-page":"606","article-title":"MYST acetyltransferases interact with SETBP1 and are a targetable therapeutic vulnerability in SETBP1-mutant leukemia","volume":"7","author":"Carlson","year":"2026","journal-title":"Blood Cancer Discov"},{"key":"2026070103103090600_bib8","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1158\/2159-8290.CD-24-1517","article-title":"Catalytic inhibition of KAT6\/KAT7 enhances the efficacy and overcomes primary and acquired resistance to menin inhibitors in MLL leukemia","volume":"15","author":"Gordon","year":"2025","journal-title":"Cancer Discov"},{"key":"2026070103103090600_bib9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41586-018-0387-5","article-title":"Inhibitors of histone acetyltransferases KAT6A\/B induce senescence and arrest tumour growth","volume":"560","author":"Baell","year":"2018","journal-title":"Nature"},{"key":"2026070103103090600_bib10","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-26-0136\/3799586\/bcd-26-0136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/4\/506\/3806867\/bcd-26-0136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/4\/506\/3806867\/bcd-26-0136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:20:46Z","timestamp":1782894046000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/7\/4\/506\/786167\/KATs-in-the-MYST-A-New-Therapeutic-Vulnerability"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":10,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,6,1]]},"published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-26-0136","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}